ArticlePloS one2026
Beyond individual markers: Prognostic value of the combined CEA/PNI score in metastatic colorectal cancer as a predictor of survival.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malnutrition and systemic inflammation significantly worsen the prognosis of oncology patients, contributing to 10-20% of cancer-related deaths. While the Carcinoembryonic Antigen (CEA) reflects tumor burden, the Prognostic Nutritional Index (PNI) captures nutritional and immune status. This study aimed to evaluate whether the combination of CEA and PNI provides superior prognostic stratification compared to either biomarker alone in patients with metastatic colorectal cancer (mCRC). This retrospective cohort study analyzed data from 512 mCRC patients at baseline and at the first response assessment (after two months of systemic treatment). Patients were stratified into four groups based on CEA (<5 or ≥5 ng/mL) and PNI (<37.52 or ≥37.52). Overall Survival (OS) and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method and Cox regression. Our results showed that the prevalence of PNILOW was 49.8% at diagnosis and increased to 54.4% after chemotherapy (p = 0.047). PNI and Body Mass Index (BMI) status alone were not significant predictors of OS or PFS. In contrast, CEA was a powerful indicator, with CEAHIGH consistently predicting worse OS and PFS. Crucially, the combined CEA/PNI score provided the strongest discrimination. Patients with the high-risk profile (CEAHIGH/PNILOW) had a significantly increased risk of death (HR 2.41, p = 0.01) and progression (HR 2.30, p < 0.01) at baseline, compared to the lowest-risk group (CEALOW/PNIHIGH). This elevated risk was maintained at the first assessment (HR 2.30, p < 0.01 for death and HR 6.81, p < 0.01 for progression). We conclude that PNI alone is insufficient to predict survival in mCRC patients. However, its integration with CEA creates a robust, easily obtainable biomarker that provides superior prognostic stratification by combining information on tumor burden and host systemic status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.